Darren Charlton Smith bought $20k of TLX
Group Chief Financial Officer at Telix Pharmaceuticals Ltd. 2,071 shares at an average of $9.66, traded Sep 7, 2026, filed Sep 14, 2026.
Score components
- +22RoleCFO
- 0Trade size$20k at market
- +3Relative to holdingsHoldings up 17%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-061944, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 7, 2026 | POpen-market purchase Ordinary Shares | +2,071 | $9.66 | $20k | 13,992 | 29 d ago |
Related signals
Other insiders at Telix Pharmaceuticals Ltd and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 53Moderate | TLXbuy Telix Pharmaceuticals Ltd | Christian Behrenbruch MD & Group CEO | $997k 67,935 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.